-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 16, the official website of NMPA showed that Amgen’s new imported drug Apomilast tablets was approved to be marketed for psoriasis
Apomilast tablets (formerly known as Apomilast tablets) is a small molecule inhibitor of phosphodiesterase 4 (PDE4)
Chemical structure of Apomilast tablets, picture source: drug insert
Apomilast tablets were developed by Celgene and launched in the United States in 2014 (trade name: Otezla).
In August 2019, Amgen announced that it had obtained Apomilast at a price of up to 13.
Apomilast is the first oral drug approved for psoriasis in the past 20 years and the first oral drug approved for PsA in the past 15 years
Such a heavy variety naturally attracts the active layout of domestic enterprises
According to the Insight database, in addition to Amgen, there are six domestic companies whose applications for the listing of Apmaster tablets are under review
From the Insight database (http://db.